Results 91 to 100 of about 5,352 (210)

Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in Asian participants with human immunodeficiency virus 1 infection: A sub-analysis of phase 3 clinical trials

HIV Research & Clinical Practice, 2019
Background: The efficacy and safety of a single tablet regimen (STR) of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) was analyzed in Phase 3 clinical trials in antiretroviral therapy (ART)-naive and ART-experienced Asian ...
Yeon-Sook Kim, Shinichi Oka, Ploenchan Chetchotisakd, Amanda Clarke, Khuanchai Supparatpinyo, Anchalee Avihingsanon, Winai Ratanasuwan, Sasisopin Kiertiburanakul, Kiat Ruxrungtham, SangYoun Yang, Susan Guo, YaPei Liu, Moupali Das, Do Tran, Damian McColl, Roberto Corales, Chris Nguyen, David Piontkowsky   +17 more
doaj   +1 more source

Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults

Pulmonary Circulation, 2019
Riociguat, a first-in-class soluble guanylate cyclase stimulator, is approved for the treatment of pulmonary arterial hypertension (PAH), a serious potential complication of human immunodeficiency virus (HIV) infection. This open-label study investigated
Edwin DeJesus, Soundos Saleh, Sue Cheng, Dorina van der Mey, Corina Becker, Reiner Frey, Sigrun Unger, Wolfgang Mueck   +7 more
doaj   +1 more source

A Stability-indicating High Performance Liquid Chromatographic Method for the Determination of Cobicistat [PDF]

, 2015
A new reverse phase – high performance liquid chromatography (RP-HPLC) have been developed and validated for theestimation of Cobicistat in bulk drug and pharmaceutical dosage form.
KALYANI, K. (K), ANURADHA, V. (V)
core  

Inhibition of human cytochromes P450 in vitro by ritonavir and cobicistat

, 2017
Objectives Ritonavir and cobicistat are strong inhibitors of human cytochrome P450-3A (CYP3A) isoforms, and are used clinically as pharmacokinetic boosting agents for other antiretroviral drugs. Data reported by the manufacturer suggest
Gerd Mikus, Timothy Tran, Tianmeng Chen, Md Amin Hossain, David J Greenblatt   +4 more
core   +1 more source

NEW ANALYTICAL METHOD VALIDATION REPORT AND FORCED DEGRADATION STUDIES FOR ASSAY OF ELVITEGRAVIR, TENOFOVIR, EMTRICITABINE AND COBICISTAT BY RP-UPLC

, 2017
The main aim of the present work is to develop and validate a simple, specific, efficient, accurate, and precise stability-indicating rapid reversed phase ultra performance liquid chromatographic method is developed for the simultaneous determination of ...
K. Kranthi Kiran*, Dr. A. Srinivasa Rao, Prof. D. Gowri Sankar
core   +1 more source

Abstracts From AIDS 2026, the 26th International AIDS Conference, 26 – 31 July 2026 Rio de Janeiro, Brazil & virtual

Journal of the International AIDS Society, Volume 29, Issue S4, July 2026.
wiley   +1 more source

Pharmacokinetic interaction between single and multiple doses of darunavir, in combination with cobicistat or ritonavir, and single-dose dabigatran etexilate in healthy adults

AAPS Open
Objective Darunavir (DRV) is a P-glycoprotein (P-gp) inhibitor. Dabigatran etexilate, prodrug of the anticoagulant dabigatran, is a P-gp probe substrate. This study evaluated the effect of single and multiple doses of DRV, coadministered with cobicistat (
Sandy Van Hemelryck, Erika Van Landuyt, Jay Ariyawansa, Martyn Palmer, Martine J. C. Kothe, Caroline Pollefliet   +5 more
doaj   +1 more source

UPLC SEPARATION ANALYSIS OF EMTRICITABINE, TENOFOVIR, COBICISTAT AND ELVITEGRAVIR FROM THEIR DEGRADATION PRODUCTS [PDF]

, 2016
Objective: A simple, rapid, accurate and precise stability-indicating UPLC analytical method has been developed and validated for the quantitative analysis of Emtricitabine, Tenofovir, Cobicistat and Elvitegravir in bulk drugs and combined dosage forms ...
P., Prahlad, N., Ravindra, S. K., Mastanamma, Rao M., Venkata Basaveswara, P., Revathi Naga Lakshmi   +4 more
core   +1 more source

Pharmacokinetic boosting of olaparib: Study protocol of a multicentre, open-label, randomised, non-inferiority trial (PROACTIVE-B)

Contemporary Clinical Trials Communications
Background: Pharmacokinetic (PK) boosting is the intentional use of a drug-drug interaction to enhance systemic drug exposure. PK boosting of the anticancer drug olaparib, a CYP3A-substrate, has the potential to reduce PK variability, side effects and ...
Joanneke K. Overbeek, Niels A.D. Guchelaar, Ma Ida Mohmaed Ali, Muriëlle Sark, Carolien Hovenier, Wietske Kievit, Marjolijn J.L. Ligtenberg, Petronella B. Ottevanger, Haiko J. Bloemendal, Stijn L.W. Koolen, Ron H.J. Mathijssen, Ingrid A. Boere, Alwin D.R. Huitema, Gabe S. Sonke, Frans L. Opdam, Rob ter Heine, Nielka P. van Erp   +16 more
doaj   +1 more source

Switch to bictegravir/emtricitabine/tenofovir alafenamide in people living with HIV aged 65 years or older: BICOLDER study – IMEA 057

Journal of Infection and Public Health
Background: Polymedication and comorbidities are frequent in aging people with HIV (PWH) and often associated with elevated incidences of adverse events (AEs) and drug-drug interactions (DDIs).
Minh P. Lê, Clotilde Allavena, Véronique Joly, Lambert Assoumou, Valentina Isernia, Faiza Ajana, Didier Neau, Diane Descamps, Charlotte Charpentier, Aïda Benalycherif, Bao Phung, Gilles Peytavin, Roland Landman   +12 more
doaj   +1 more source